Aquavit Pharmaceuticals, a private US-based life science company, has announced the appointment of David Goldberg as chief medical officer. 6 March 2014
Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch Doliveux, saying that Jean-Christophe Tellier, currently executive vice president, Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee as of March 1, 2014. 21 February 2014
US drug developer Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. 18 February 2014
Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Graham Hetherington, chief financial officer, has decided to step down from the company. 13 February 2014
The founder of Douglas Pharmaceuticals, Sir Graeme Douglas, has announced his retirement as the company’s managing director, effective February 1. 4 February 2014
E. Merck KG, which combines the financial interests of the Merck family and is general partner of Germany’s Merck KGaA (MRK: DE) with an interest of 70%, announced at this year's General Partners' Meeting, the family partners elected their representatives to the Family Board, which is the supervisory body of E. Merck KG. 28 January 2014
Privately-held US drugmaker Purdue Pharma has appointed Mark Timney as president and chief executive. He succeeds John Stewart, who has retired from Purdue. 27 January 2014
Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Susan Kilsby will become non-executive chairman, replacing Matthew Emmens who is retiring at the company’s AGM on April 29. 23 January 2014
French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision to set up its own oncology team to commercialize Somatuline Depot (lanreotide) in neuroendocrine tumors (NETs) in the USA. 22 January 2014
Takeda Pharmaceutical, Japan’s largest drug company, has appointed Emiliangelo Ratti as head of its CNS Drug Discovery Unit, Pharmaceutical Research Division. 15 January 2014
Swiss drug major Novartis said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology, will leave the company with immediate effect having decided to “pursue a career opportunity outside of the organization.” 13 January 2014
German privately-owned pharma company Priaxon AG has appointed Constance Hoefer as chief development officer (CDO) to oversee non-clinical and early clinical development. 9 January 2014